Bayer AG

General information

Bayer AG
Kaiser-Wilhelm-Allee 1
51368 Leverkusen, North Rhine-Westphalia
Germany

Contact person: Thomas Kornek, Senior Manager, Investor Relations
Company main phone: +49 (214) 301
Website: https://www.bayer.com

Year founded:	1863
Source of foundation:	Independent foundation
No. of employees:	Worldwide: 97922

Corporate description / mission:
Bayer AG is a German chemical and pharmaceutical company, which focuses on human and veterinary pharmaceuticals; consumer healthcare products; agricultural chemicals and biotechnology products; and polymers. The company's products include adempas, adalat, baytril, etc.

State of ownership: Publicly listed on stock exchange
Headquarters: Yes
IPO (year): 1988

Categorization

Sector:

Pharma (fully integrated)

Subsector:

Anti-infectives
Antibodies
Cell therapy
Gene therapy
Immunotherapy
Nucleic acid drugs
Peptides
Small molecule therapeutics
Stem cells

Primary therapeutic areas:

Cardiovascular / cardiology
Digestive system / gastroenterology
Diseases of the blood and blood-forming organs & immune disorders / hematology / immunology
Diseases of the eye / ophthalmology
Diseases of the nervous system / neurology
Endocrine, nutritional and metabolic diseases / endocrinology
Genitourinary system / Urology
Infectious and parasitic diseases / infectiology / parasitology
Musculoskeletal system and connective tissue / Orthopedics
Neoplasms / cancer / oncology
Respiratory / pulmonology
Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified

Business model:

Manufacturer
R&D
Supplier / Distributor

Customer segments:

Consumers (mass market)
Hospitals
Physicians / doctors

Distribution:

Direct (own sales force)

Summary Products / Services / Technologies

Number of Biotech Products

Phase I:	23
Phase II:	9
Phase III:	12
On the market:	7

Description of products:
Anetumab Ravtansine for cancer multi indication
Anti-FXI Antibody - Anticoagulation
Anti-TFP1 antibody for Hemophilia
Copanlisib (PI3K Inhibitor) for Cancer, etc

Financing details

Fiscal year (end of) 2022

Revenues:	EUR 50'739.00M
R&D expenses:	EUR 6'572.00M
Net earnings:	EUR 4'150.00M

No. of shares:	982'424'000
Market cap. / valuation:	EUR 54'612.95M